lexgenleucel-T (VRX496)
/ VIRxSYS Corp
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 26, 2019
Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV
(clinicaltrials.gov)
- P1/2; N=25; Completed; Sponsor: University of Pennsylvania; Active, not recruiting ➔ Completed
Clinical • Trial completion
1 to 1
Of
1
Go to page
1